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Abstract
Poly(ADP-ribose) polymerase 1 (PARP1) inhibitors were recently shown to have clinical impact
in a number of disease settings, particularly as related to cancer therapy, treatment for
cardiovascular dysfunction, and suppression of inflammation. The molecular basis for PARP1
inhibitor function is complex, and appears to depend on the dual roles of PARP1 in DNA damage
repair and transcriptional regulation. Here, the mechanisms by which PARP-1 inhibitors elicit
clinical response are discussed, and strategies for translating the preclinical elucidation of PARP-1
function into advances in disease management are reviewed.
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INTRODUCTION
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Poly(ADP-ribose) polymerase 1, PARP1, is the founding member of an enzyme superfamily
that serves to add PAR (poly(ADP) ribose) moieties onto target proteins, and in doing so to
exerts powerful effects on a number of biological processes critical for cell growth and
survival (Gibson and Kraus, 2012). At present, there are at least 17 members of the PARP
(and related tankyrase) superfamily; these play important and varied roles in DNA repair,
transcriptional regulation, chromatin dynamics, response to hypoxia, cell cycle control,
oncogene activity, cell death, maintenance of genomic integrity, and spindle pole regulation
(Lupo and Trusolino, 2014). PARP1 is the most abundant member of this family, and shares
overlapping functions with the related protein PARP2. In the last decade, intensive focus has
been placed on discerning the mechanisms that regulate PARP1 function and the
downstream consequence of PARP1 biological activity, given provocative preclinical and
clinical observations with regard to the promise of PARP1/2 inhibitors as a means to combat
a subset of human malignancies.
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From a structural standpoint, PARP1 is composed of six functional domains: there are two
homologous zinc finger domains (Zn1 and Zn2) that are associated with detection of DNA
damage; a third zinc finger domain that is responsible for coupling the DNA-binding and
enzymatic functions of PARP1 (Zn3); a BRCT domain that controls protein – protein
interactions, a WGR domain that promotes inter-domain communication, and a C-terminal
catalytic domain that controls PAR catalysis (Steffen et al., 2013). Notably, PARP1 function
is known to be induced in response to a wide arrays of cellular signals and stresses,
including nucleosome conformational changes (Ji and Tulin, 2010; Thomas et al., 2014),
altered interacting partners, and induction signaling pathways associated with oxidative,
oncogenic, genomic, or inflammatory stress (Luo and Kraus, 2012), but has perhaps been
most extensively characterized in the presence of DNA damage. In the context of DNA
damage, PARP1 binds damage DNA dependent on the N-terminal domains; this event
activates the C-terminal domain to hydrolyze NAD+ (nicotinamide adenine dinucleotide), a
cofactor for redox reactions and effector of other cellular events including signal
transduction and gene regulation; this then generates PAR chains. Through this mechanism,
PARP1 covalently attaches PAR subunits to the Glu, Lys, or Asp residues of target proteins.
Similar mechanisms of regulation have been ascribed to PARP2, but there are structural
differences, and studies with Parp1−/− mice (Wang et al., 1995) demonstrate that PARP-1
accounts the majority of total cellular PARP activity. Thus, it is generally thought that the
cellular consequence of PARylation is largely driven by PARP1, and that the therapeutic
effects of PARP1/2 inhibitors are likely to be manifest through modulation of the PARP1
enzyme.
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Recent studies have begun to reveal the mechanisms by which PAR exerts its biological
effects (Gibson and Kraus, 2012; Lupo and Trusolino, 2014; Schiewer and Knudsen, 2014).
PARylation is recognized by PAR-recognizing proteins (“readers”), that contain
macrodomains, PAR-binding zinc-fingers (PBZFs), PAR-binding linear motifs (PBMs), and
WWE-domains (Barkauskaite et al., 2013). Removal of PAR is also highly regulated, and
can occur within minutes (Alvarez-Gonzalez and Althaus, 1989; Gagne et al., 2006).
Specialized macrodomain proteins such as PARG (Poly ADP-ribose glycohydrolase)
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remove PAR and thereby also act as “erasers” (Slade et al., 2011), leaving behind monoADP ribosylation that is more stable but is ultimately resolved (Jankevicius et al., 2013).
The majority of PARP1 activity is self-directed, and as such, auto-PARylation of PARP1 is
a known readout to monitor PARP1 activity. However, proteomic analyses using various
human cancer cell lines of demonstrated that outside of auto-modification, the substrates
modified by PARP1 are divergent (dependent on cell context), and identify nuclear targets
of PARP1 that include DNA repair factors, transcription factors, chromatin remodeling
factors, and histones (Zhang et al., 2013). Specific targets of PARylation in the DNA
damage response include ALC1 (also known as CHD1L), a macrodomain-containig ATPase
and remodeling enzyme that is attracted to sites of PAR formation and therein is thought to
facilitate chromatin remodeling at sites of DNA damage (Ahel et al., 2008; Gottschalk et al.,
2009). The macrodomain proteins macroH2A.1 also responds to PAR formation and
initiates chromatin compaction events that likely contribute to DNA repair (Timinszky et al.,
2009). While these functions exemplify the role of PAR-binding proteins on DNA damage
associated chromatin alterations, other PARylated proteins play more proximal roles in
DNA repair and/or DNA damage checkpoints, including the PBZFs APLF (aprataxin PNKlike factor) and CHFR (checkpoint protein with FHA and RING domains) (Ahel et al., 2008;
Rulten et al., 2011). Distinct from these downstream effects of PARP-1 are the PARylation
events that modulate transcriptional regulation. Both PARP-1 and PARG play established
roles in gene expression through via regulating PARylation and PAR-degradation at target
gene regulatory loci (Frizzell et al., 2009; Krishnakumar et al., 2008). Modulation of the
KDM5B (JARID1B) histone demethylase provides yet a different mechanism of
transcriptional regulation by PARP-1, wherein PARylation of KDM5B suppresses
chromatin interaction, thereby sustaining of histone modifications that facilitate gene
expression (H2K4me3)(Krishnakumar and Kraus, 2010). Observations in lower eukaryotes
have also provided insight into transcriptional regulation by PARP-1, wherein PARP-1
orchestrates chromatin alterations and engages differential transcriptional networks
downstream of cellular stresses, such as in response to heat shock (Petesch and Lis, 2012;
Sala et al., 2008). These collective observations further implicate PARP1 as a critical
effector of DNA repair, transcriptional regulation, and chromatin dynamics, and underscore
the need to discern which of the variant PARP1 functions underlie the molecular rationale
for targeting PARP1 function in the clinical setting, and for determining which disease types
might most benefit from treatment with a PARP1 inhibitor. This review will focus on the
dual roles of PARP1 in DNA repair and transcriptional regulation and as relates to clinical
utility (Figure 1), highlighting PARP1 functions that are being exploited in on-going clinical
trials.
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THE ROLE OF PARP1 IN SENSING DNA DAMAGE AND FACILITATING DNA
REPAIR
Of all the known molecular functions of PARP1, perhaps the best characterized is that
associated with DNA damage and DNA repair. From an enzymatic standpoint, DNA
damage-induced binding and activation of PARP1 is thought to promote a relaxed chromatin
structure and to facilitate access of DNA repair enzymes to bind damaged lesions. PARP1
plays a well-established role in base excision repair (BER), and as part of a core complex
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composed of DNA ligase III, Pol-B, and XRCC1 (Beck et al., 2014). This DNA repair
pathway resolves single base pair lesions that occur as a result of genetic insults, including
deamination, oxidation, and alkylation. PARP1 senses these lesions, binds, synthesizes PAR
at the lesion, and recruits the BER machinery to the site. Other pathways that resolve or
generate single-strand breaks, such as nucleotide excision repair (NER) and mismatch repair
(MMR) have also been suggested to invoke PARP1 activity (Liu et al., 2011; Robu et al.,
2013), although the role of PARP1 in these processes is less well defined. It is clear that
PARP1 activity is significantly enhanced in response to ultraviolet (UV) radiation and the
generation of UV-induced thymine dimers. Consistent with these functions, PARP1/2
inhibitors sensitize cells to single-strand DNA breaks and base damage.
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More recently, a role for PARP1 in double strand DNA break repair has emerged (Helleday
et al., 2005; Wang et al., 2006). PARP1 has been found in association with double strand
DNA breaks, and PARylation at double strand breaks is thought to facilitate recruitment of
appropriate double strand DNA break repair factors. Moreover, PARP1 binding and function
have been implicated in the resolution of stalled DNA replication forks (Bryant et al., 2009;
Ying et al., 2012). Both double strand DNA break repair and stalled replication forks invoke
homologous recombination (HR) and non-homologous end joining (NHEJ) pathways, and a
potential role for PARP1 in these processes further substantiates the rationale for utilization
of PARP1 inhibitors in the clinical setting. The functional role of PARP1 in double-stranded
DNA break repair has been extensively reviewed elsewhere (Golia et al., 2015; Li and Yu,
2014); briefly, PARP1 binds to double-stranded DNA breaks within milliseconds of the
damage event, induces PARylation, and attracts the MRN (Mre11, Rad50, NBS1) complex
for homologous HR mediated repair. After double strand DNA break resection, resultant
single-strand DNA is bound by Rad51, which facilitates template dependent DNA synthesis.
Critical to this process are BRCA1 and BRCA2, which facilitate Rad51 loading, and
resultant efficient completion of HR-mediated repair. Recent studies further implicate
PARP1 in this process; BRCA1 is itself a substrate of PARP1, and the PARylation of
BRCA1 DNA-binding domain attenuates its function. Suppression of BRCA1 PARylation
resulted in hyperactive HR and genomic instability, demonstrating for the first time that
PARP1 and BRCA1 might paradoxically both support and suppress HR. With regard to the
more error-prone double-stranded DNA break repair pathway of NHEJ, a potential role for
PARP1 was implicated by the observation that the enzyme is frequently found in complex
with and to modify DNA-PK, a kinase whose function is critical for NHEJ-mediated DNA
repair. However, the overall contribution of PARP1 to classical NHEJ remains uncertain. A
potential role for PARP1 in alternative end joining (A-EJ) (Robert et al., 2009), a process
that slowly resolves radiation-induced double strand DNA breaks, has also been proposed
based on the requirement of PARP1 for A-EJ mediated repair in cells that lack the capacity
for NHEJ. Moreover, substantial evidence implicates PARP-1 in backup end joining (BNHEJ) (Iliakis, 2009). Collectively, the function of PARP1 in DNA repair has expanded
from an established role in BER to multiple additional functions in both single and double
strand DNA break repair processes. These properties of PARP1 are thought to play a major
role in underpinning the function of PARP1 inhibitors in anticancer therapy, as evidenced by
the initiation of multiple PARP1 inhibitor trials in this space.
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PARP1 INHIBITION AS A STRATEGY FOR TARGETING DNA REPAIR IN
CANCER
The concept of targeting PARP1 function in cancer therapy is not new––PARP1 inhibitors
emerged in the 1980s, and were shown to both suppress DNA repair, and to enhance the
response to DNA damaging agents (Durrant and Boyle, 1982; Nduka et al., 1980). PARP1
inhibitors generally function to suppress covalent attachment of ADP-ribose (monomers or
polymers) to PARP1 substrates. With the development of more potent, specific, and
effective PARP1 inhibitors, numerous clinical trials are now investigating these agents as an
approach to target DNA repair in cancers (Figure 2 and www.clinicaltrials.gov).
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The vast majority of current or completed PARP1 inhibitors clinical trials focus on the use
of these agents in cancer patients (Figure 2A). Additionally, most of these studies are phase I
trials (examining the safety and tolerability of these agents) or phase II trials (investigating
the efficacy of these inhibitors in early studies) (Figure 2B). To date, there are 9 active phase
III trials (which are large randomized studies definitively assessing the efficacy of PARP
inhibitors compared to standard therapies, usually with a survival endpoint). In terms of
disease sites, most of the studies targeting a particular cancer focus on either ovarian cancer
(23 studies), breast cancer (13 studies), or breast and ovarian cancer (7 studies). It is also
likely that many of the trials allowing for patients with any type of solid cancers (27 studies)
have likely enrolled a disproportionately higher rate of patients with breast or ovarian
cancer, compared to other cancer types. PARP1 inhibitors have been explored as either a
monotherapy (42 trials) or in combination with conventional chemotherapy and/or
radiotherapy (70 trials) (Curtin and Szabo, 2013) (Figure 2D).
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Monotherapy strategies are based on the concept that PARP1 inhibitors may be effective in
subsets of cancers that harbor defects in the HR pathways, based on the theoretically
increased reliance on PARP1-dependent DNA repair mechanisms including BER (Farmer et
al., 2005; McCabe et al., 2006). As predicted by preclinical studies, tumor cells with
BRCA1/2 mutations proved highly sensitive to PARP1 inhibitors (Sandhu et al., 2010). In
this situation, it is proposed that crippling PARP1 activity in the background of HR
deficiency results in accumulation of unrepaired DNA breaks to the extent that the level of
genomic instability achieved becomes non-viable. While initially conceived during the era
wherein PARP1 was largely associated with BER, this hypothesis is increasingly attractive
given the new state of knowledge regarding PARP1 function in double strand DNA break
repair. Furthermore, it was posited that PARP1 and the HR pathway play distinct roles in
restarting stalled DNA replication forks that occur in response to replication stress, therefore
putting forth the provocative hypothesis that PARP1 inhibitor function could be at least
partially attributed to suppressing DNA replication fork progression. Therefore in the setting
of disabled HR though either somatic or germline alterations, the inhibitor of PARP1
activity leads an inability to repair DNA damage thus creating a synthetic lethal situation for
the tumor cells.
To date, the use of synthetic lethality has been most effectively exploited in the context of
BRCA1/2 deficient breast and ovarian cancers (Sonnenblick et al., 2015). Patients with
germline mutations in BRCA1/2 are highly susceptible to the development of ovarian and
Mol Cell. Author manuscript; available in PMC 2016 June 18.

Knudsen et al.

Page 6

Author Manuscript
Author Manuscript

breast cancers. In preclinical modeling in this disease type has confirmed that
hypersensitivity to PARP1 inhibitors is observed when BRCA function is compromised.
Building on these observations, a first in man, Phase I, clinical trial using the PARP1/2
inhibitor olaparib as a single agent in advanced cancers showed objective responses in
patients carrying germline BRCA1/2 mutation (Fong et al., 2009). Similar results were
observed in expansion cohorts assessing responses in ovarian cancer patients with BRCA
mutations, and in Phase II trials that pre-selected for breast and ovarian cancer patients
carrying BRCA mutations (Audeh et al., 2010; Tutt et al., 2010). Furthermore, a large
randomized phase II study of olaparib versus placebo in patients with recurrent serous
ovarian cancers has demonstrated significant improvements in progression-free survival in
favor of olaparib treatment, with greater benefit seen in patients harboring a BRCA mutation
(Ledermann et al., 2012; Ledermann et al., 2014). These trials have recently led to the
regulatory approval of olaparib first by the European Medicines Agency (EMA), and then
by the Food and Drug Administration (FDA). Currently, there are a large number of clinical
trials for human malignancies using PARP1 inhibitors as a monotherapy, with a large
number of these requiring or enriching for either germline BRCA1/2 mutation or other
evidence of HR alterations as inclusion criteria (Figure 2E). However, variable response is
observed even within published cohorts of patients with BRCA mutations, and PARP1
inhibition can result in improved outcomes even within cohorts with germline wild-type
BRCA (Ledermann et al., 2014), thus indicating that effectors of the response to PARP1
inhibitors reach beyond that of BRCA/HR status.
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In addition to studies assessing PARP1 inhibitor monotherapy, there are numerous clinical
trials, across a range of cancer sites, which employ combination therapy strategies
incorporating PARP1 inhibitors with cytotoxic therapies (Figure 2D). These trials are
largely based on preclinical studies demonstrating that the suppression of DNA repair
pathways by PARP1 inhibitors can potentiate the effects of conventional chemotherapy or
radiation therapy (reviewed in (Curtin and Szabo, 2013)). Indeed, Parp1 deficient cells or
cell treated with PARP-1 inhibitors are hypersensitive to DNA methylating agents,
topoisomerase I inhibitors, and radiotherapy, albeit secondary to slightly differing
mechanisms (Horton and Wilson, 2013; Liu et al., 1999; Masutani et al., 1999; Tentori et al.,
2002; Wang et al., 1995). DNA methylating agents (e.g., temozolamide) methylate DNA at
purine bases, and excision of the resultant N-methylpurines results in a DNA single strand
break repaired by PARP1. Thus, by suppressing repair of these single strand breaks, PARP1
inhibition potentiates temozolamide effects. Similarly, topoisomerase I inhibitors (e.g.,
topotecan or irinotecan) result in DNA lesions repaired by BER, which is blocked by
PARP1 inhibitors. Likewise, radiation therapy induces both DNA single-stranded breaks
(SSB) and double-stranded breaks (DSB), and PARP1 inhibition can suppress the repair of
SSBs that subsequently convert to DSBs upon collision with replication forks in S-phase. It
is also likely that PARP1 inhibitors can directly inhibit the repair of DSBs generated by
exposure to radiation. Additional in vitro and in vivo data support the potentiation of other
cytotoxic agents in a context-specific manner, but the mechanisms underlying such synergy
are still being explored. Notably, clinically utilized PARP1/2 inhibitors have also been
reported to function in part by trapping PARP1 and PARP1 at sites of DNA damage, thus
revealing important insight into the molecular basis by which suppression of PARP1/2
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activity can cooperate with DNA damaging agents (Murai et al., 2012). As a consequence of
these collective preclinical data, ongoing clinical trials have assessed the combination of
PARP1 inhibitors with cytotoxic chemotherapy or radiation therapy, mostly in patient
cohorts not screened for any particular DNA repair alterations. Ironically, the largest phase
III study assessing combination therapy (with the addition of the presumed PARP1 inhibitor
iniparib to gemcitabine and cisplatin) failed to show any additive anti-tumor effects with
iniparib (O’Shaughnessy et al., 2014), but it was later determined that this agent actually has
poor selectivity toward PARP function, and does not meet the current criteria for a bona fide
PARP1 inhibitor (Patel et al., 2012). While this study temporarily dampened enthusiasm of
the medical community for PARP1 inhibitor trials, continued reports of anti-tumor efficacy
of combination therapy in both preclinical and clinical settings (Bang et al., 2013; Oza et al.,
2014; Sonnenblick et al., 2015) has rekindled interest in PARP1 inhibitors, with over 110
clinical trials, most of them ongoing, employing combination therapies incorporating these
agents (Figure 2 and www.clinicaltrials.gov).

TRANSCRIPTIONAL REGULATORY FUNCTIONS OF PARP1 AS
ASSOCIATED WITH HUMAN DISEASE
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In parallel to the realization that PARP1 encompasses a broad scope of DNA repair
responses, it is evident that a major function of PARP1 in the absence of DNA damage is to
serve as a potent modulator of gene transcription, through activities that include
transcription factor regulation, chromatin regulation, and the ability of PARP1 to serve as a
context specific transcriptional co-regulator and chromatin modifier (Gibson and Kraus,
2012; Kraus and Hottiger, 2013; Schiewer and Knudsen, 2014). Similar to DNA-PK
(Goodwin and Knudsen, 2014), PARP1 interacts with RNA pol II complexes, and can both
up- or down-regulate gene expression. Moreover, PARP1 can promote histone H1 exchange
at the promoters of actively transcribed genes (Krishnakumar et al., 2008), thus facilitating
an active chromatin state required for gene expression. In the context of cancer, PARP1mediated transcriptional regulation is known to modulate transcriptional regulators whose
functions are critical for tumor suppressor function (including p53), oncogene activity,
effectors of metastases, chromatin modulators associated with human malignancy,
maintenance of stemness/pluripotency, and numerous cell survival and adaptation pathways.
HIF1-alpha function has also been shown to be sensitive to PARP1 (Martin-Oliva et al.,
2006), therefore linking PARP1 activity to the response to hypoxia. Finally, a specialized
role for PARP1 was revealed in hormone-dependent cancers (e.g., breast and prostate
cancer), as PARP1 binds to and modulates the activity of a large number of nuclear
receptors, including estrogen receptors alpha and beta, the progesterone receptor, and the
androgen receptor (Schiewer and Knudsen, 2014). Moreover, PARP1 can modulate the
transcription factor ERG activity and potentiate chromosomal rearrangements in prostate
cancer (Brenner et al., 2011; Schiewer and Knudsen, 2014). Given the mounting evidence
that PARP1 inhibitors show clinical efficacy in a subset of human malignancies, it has been
hypothesized that these transcription regulatory functions of PARP1 significantly contribute
to the observed anti-tumor activity. This hypothesis is further supported by evidence that
PARP1 inhibitors confer significant benefit even in the absence of known BRCA mutations,
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although this may also in part be related to the loss of other DNA repair genes (Ledermann
et al., 2014)
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Importantly, PARP1-mediated transcriptional control appears to significantly impact
processes with farreaching implications outside of cancer. Across a range of acute medical
conditions, such as circulatory shock, myocardial infarction, and stroke, PARP1 has been
demonstrated to promote the expression of pro-inflammatory genes which contribute to the
pathology of these diseases (Curtin and Szabo, 2013). PARP1 interacts with a number of
transcription factors and co-factors, including NFkB, NFAT, AP-1, YY1, sp1, and SIRT1,
which have been associated with inflammatory gene expression (Bai and Virag, 2012). In
fact, one of the best characterized interactions between PARP1 and a transcription factor is
that with NFkB in cellular stress responses, such as inflammation (Curtin and Szabo, 2013;
Hassa and Hottiger, 2002). Studies have shown that PARP-1 enzymatic activity directly
affects NFkB-mediated transcriptional activity. In particular, PARP1 PARylates both
subunits of NFkB, p50 and p65, in vitro and this PARylation inhibits the ability of NFkB to
bind to DNA (Kameoka et al., 2000). Moreover, auto-PARylation of PARP1 also promotes
the DNA binding ability of NFkB (Chang and Alvarez-Gonzalez, 2001) Coactivation of
NFkB-mediated transcriptional programs by PARP1 can enhance expression of inducible
nitric oxide synthase (iNOS), cell adhesion molecules (I-CAM, V-CAM, and L-CAM), and
matrix metalloproteinases, all of which foster an inflammatory signaling cascade (Garcia
Soriano et al., 2001; Ha et al., 2002; Hassa and Hottiger, 1999; Oliver et al., 1999).
Pharmacologic inhibition or genetic knockout of PARP1 suppresses levels of inflammatory
cytokines, such as TNF-α, IL-1β, IL-6, and IL-12, in animal models of inflammation (Shall
and de Murcia, 2000). This may have relevance to the antitumor activity of PARP inhibitors.
Moreover, in the context of circulatory shock, studies demonstrated that bacterial wall
lipopolysaccharides (LPS, endotoxin) result in PARP1 activation in macrophages, which
induces the expression of iNOS and results in the overproduction of nitric oxide, leading to
development of vascular contractile failure. Inhibition or knockdown of PARP1 attenuates
the tissue infiltration of inflammatory cells, improves vascular and organ function, and
produces survival benefits in rodent models of circulatory shock (Curtin and Szabo, 2013;
Szabo et al., 1996). Likewise, in the context of myocardial infarction or cardiac
transplantation, PARP1 inhibition exerts a significant cardioprotective effect in rodent
models, resulting in blunting of the inflammatory response, shielding from reperfusion
injury, diminished infarct size, increased cardiac contractility and improved survival (Curtin
and Szabo, 2013). In addition to cardiac ischemia, PARP1 inhibition also protects from
neuronal injury in the context of ischemic strokes. In ischemic stroke models in monkeys,
PARP1 inhibition significantly reduced cerebral infarct volumes and neurological deficits
(Matsuura et al., 2011). It should be noted that while suppression of inflammation is a
common theme across each of the highlighted medical conditions (shock, myocardial
infarction, and stroke), the antiinflammatory properties of PARP1 inhibition only partially
explain the efficacy of these agents in these situations. Other contributing mechanisms
include inhibition of excitotoxicity that can trigger calcium overload resulting in cell
necrosis in ischemic stroke, limitation of DNA strand breakage in the context of oxidative
stress following myocardial infarction, and effects on cellular energetics and cell death
signaling in all of these scenarios.
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Modulation of transcription by PARP1 extends beyond cancer drivers and inflammatory
gene programs, often in a context-specific manner. For example, during neuronal
differentiation, PARP1 was shown to be instrumental in promoting neurogenic gene
expression events through modifying transcriptional co-repressors and displacing them from
the promoters of pro-neurogenic genes (Ju et al., 2004). Similar hypotheses have emerged
with regard to muscle differentiation gene programs, and the concept that PARP1 elicits a
cell specific gene regulatory program is becoming evident. However, it is not clear that these
gene regulatory events are universally sensitive to enzymatic inhibitors of PARP1. In some
cases, PARP1 residence on chromatin is sufficient to modulate gene expression events, and
to modulate chromatin function. In these situations it is postulated that PARP1 acts as a
scaffold for recruitment of transcriptional modulators, including histone acetyltransferases.
Furthermore, PARP1 activity has been shown to result in significant epigenetic alterations
through modulation of CTCF (which regulates gene insulation) and Dnmt1 (a DNA
methyltransferase). Finally, PARP1 hyperactivation has been linked to mitochondrial
dysfunction (Bai et al., 2014) associated with neurodegeneration in aging, by virtue of
modulating the NAD+-Sirt1-PGC1a axis. Taken together, it is apparent that a major cellular
function of PARP1 on chromatin is to regulate gene expression, and that PARP1 sensitive
transcriptional events can exert contextspecific biologic outcomes that are of relevance for
translation of PARP1 inhibitors into the clinic.

PARP1 INHBITORS AS A STRATEGY FOR SELECTIVE MODULATION OF
TRANSCRIPTIONAL PROGRAMS
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The vast majority of PARP1 inhibitor-based clinical trials were designed and initiated to
target DNA repair in cancer (including breast and ovarian cancer), using combinations with
genotoxic stress and/or pre-selected populations known to harbor BRCA1/2 mutations.
However, there is an emerging rationale for investigating PARP1 inhibitors as
monotherapies, in part as a means to suppress transcriptional drivers of disease in the setting
of cancer and non-cancer therapy. This rationale is supported by both preclinical data, as
summarized above, as well as results from clinical studies suggesting that factors other than
homologous recombination deficiencies can impact response to PARP1 inhibitors
(Ledermann et al., 2014).
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Within the arena of malignancies, PARP1 suppression as a single agent represents a
particularly promising disease site for targeting both the DNA repair and transcriptional
functions of PARP1 in prostate cancer, based on recent discoveries linking the hormone and
DNA repair pathways. PARP1 is recruited to sites of AR (androgen receptor) function
(Schiewer et al., 2012), and is it known that both early and late stage prostate cancers are
dependent on AR function for growth and progression. Preclinical studies and ex vivo
analyses of primary human tissues showed that PARP1 inhibitors suppress AR activity, AR
dependent tumor growth, and progression to hormone therapy resistance in the absence of a
DNA damaging agent or BRCA alterations. The rationale for utilizing PARP1 inhibitors was
further enriched by the observation that AR promotes double-stranded DNA break repair
through pathways that implicates PARP1, and invokes NHEJ through DNA-PK regulation
(Goodwin et al., 2013; Polkinghorn et al., 2013). These findings provided the molecular
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basis for clinical observations which showed that anti-androgen therapy acts in concert with
radiation in patients with locally advanced disease to improve overall survival and outcome,
and suggest that PARP1 inhibitors as a monotherapy would serve to both suppress AR
activity and hormone dependent DNA repair. Moreover, chromosomal translocations that
result in hyper-expression of pro-oncogenic ERG transcription factors are common in
prostate cancer, and PARP1 was shown in preclinical models to function as an ERG cofactor
and to support ERG mediated transcriptional activity (Brenner et al., 2011). Thus, PARP1
inhibitors combinatorially suppress the function of the major transcription factors that drive
prostate cancer growth and progression. Finally, while BRCA1/2 mutations are thought to
be infrequent in prostate cancer, recent observations point toward other alterations that
compromise HR and induce sporadic “BRCAness” in this tumor type, including ATM loss.
Emerging data from the genomic study of advanced prostate cancers suggest that
homozygous mutations in DNA repair genes including ATM in up to 15% of the cases
(Beltran et al., 2013). Moreover, the lncRNA PCAT-1 is induced in this disease type and
serves to repress BRCA2, thereby conferring marked sensitivity to PARP1 inhibitors as
single agents (Prensner et al., 2014). Consistent with these preclinical findings, phase 1
studies were recently completed using the PARP1 inhibitors as single agents in two separate
trials and shown significant clinical antitumour activity in patients with advanced sporadic
prostate cancers that had progressed despite most available hormone treatments and
chemotherapy. More recently, an abstract, presented at the 2014 ESMO meeting, reported
preliminary results from an adaptive multi-part Phase II trial (TOPARP; CR-UK/11/029)
investigating the activity of the PARP1 inhibitor olaparib in 30 patients with end-stage
prostate cancer (Mateo et al., 2014). In this study, olaparib resulted in a 33% response rate,
which is quite promising for this patient population. While whole exome sequencing
revealed alterations in some DNA repair genes (eg BRCA2 and ATM) enriched among
responding patients, a significant percentage of responders did not harbor defects in these
DNA repair genes, indicating that the interaction with these genes may not explain all the
PARP inhibitor sensitivity in this disease. It has been hypothesized that the effects of
PARP1 on gene transcription may contribute to the antitumor activity of PARP inhibitors
against metastatic prostate cancer, although more data are now required to interrogate these
findings. Currently, there is an ongoing study (NCT01576172, www.clinicaltrials.gov),
which stratifies castration resistant prostate cancer patients based on ETS rearrangement
status, as ascertained by biopsy of a metastatic lesion, and then randomizes patients to
abiraterone (an agent targeting androgen synthesis) alone or in combination with the PARP
inhibitor veliparib. This study may provide additional insights on the efficacy of targeting
oncogenic transcriptional drivers in prostate cancer with PARP1 inhibitors.

Author Manuscript

Outside of cancer, while there is an abundance of preclinical data supporting the
investigation of PARP1 inhibitors as potential transcriptional regulators in non-oncological
indications such as circulatory shock, myocardial infarction, or stroke, there has been, to
date, only one completed clinical trial. This single randomized trial assessed the effect of the
PARP1 inhibitor INO-1001 in 40 patients with myocardial infarction, undergoing
percutaneous coronary revascularization (Morrow et al., 2009). While this study was not
powered to assess clinical efficacy, there was a trend towards blunting of inflammatory
response, as assessed by serial plasma c-reactive protein and IL-6 levels, with the addition of

Mol Cell. Author manuscript; available in PMC 2016 June 18.

Knudsen et al.

Page 11

Author Manuscript
Author Manuscript

the PARP1 inhibitor. The only other active non-oncologic PARP1 inhibitor trial is a phase I
study assessing safety of the “stroke-targeting” PARP1 inhibitor JPI-289 in healthy
volunteers. One may wonder – why are there >140 clinical trials of PARP1 inhibitors in the
oncological space, but only 2 studies of PARP1 inhibitors in the non-oncological space? The
answer is relatively straightforward—the oncology arena likely represents a more acceptable
space for testing drugs which inhibit DNA repair. Because many cancers are aggressive with
limited therapeutic options, cancer patients and their physicians are willing to test out novel
drugs with “potentially riskier” side-effect profiles (such as an extremely small risk of
carcinogenesis from a DNA repair inhibitor). However, these same side-effect profiles are
less acceptable to patients with less life-threatening illnesses and longer life expectancies. It
is notable that mice lacking the PARP-1 (ADPRT) gene develop normally, and show no
evidence of tumor formation, but do show some incidence of epidermal hyperplasic with
aging (Wang et al., 1995). While improvements in drug formulation and delivery can help
shorten the duration of treatment and further decrease side effects, it is unlikely that PARP1
inhibitors will be widely introduced into clinical trials assessing non-oncological indications,
unless better function selectivity (for transcriptional regulation over DNA repair) can be
achieved, until these agents gain greater traction with in the oncological space, or until more
information can be gleaned about the long-term effects of PARP1 suppression. Nevertheless,
the increasing evidence that these drugs are very well tolerated with very limited toxicity to
date in oncology trials support the further evaluation of these agents in non-cancer
indications.

CONCLUSIONS AND FUTURE DIRECTIONS
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Biochemical investigation, preclinical discovery, and clinical analyses have not only
nominated PARP1 as a viable therapeutic target for human malignancies, but suggest that
PARP1 inhibitors may be effective in cardiovascular dysfunction and inflammatory
syndromes. While recent advances suggest that the molecular basis of PARP1 inhibitor
function likely depends on the pleiotropic roles of the enzyme in DNA repair, transcriptional
regulation, and modulation of chromatin dynamics, significant gaps in understanding remain
which limit translation of these findings into the clinical setting. First, which function(s) of
PARP1 are critical for observed clinical responses? Although early studies suggest that the
transcription regulation and DNA repair associated functions of PARP1 can be functionally
segregated through mutational analyses, the molecular underpinnings of these divergent
functions remain poorly understood and are closely interlinked. Second, what molecular
markers can be identified that may predict sensitivity to PARP1 inhibitors? While the
observation that patients with germline or somatic mutation in BRCA1/2 can show
exceptional responses to PARP1 inhibitors in the oncology setting, not all patients show this
profile, or in other known DNA repair pathways. Studies should be prioritized that will
allow for a full molecular dissection of tumors that show heightened sensitivity to PARP1
inhibitors, and these observations challenged in the clinical setting. These studies should
include assessment of not only DNA repair factors that might modify response to PARP1
inhibitors, but should include investigation of up- and downstream effectors of PARP1
function (including readers, writers, and erasers of PARylation). Third, as the
transcriptional regulatory roles of PARP1 are thought to contribute to the function of
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PARP1 inhibitors as single agents, what is the genomic profile of PARP1 binding to
chromatin, and the basis of selectivity for controlling disease-relevant transcriptional
programs? Defining the PARP1 cistrome and transcriptome in human tissues and/or
preclinical models that mimic human disease would be of potentially high translational and
clinical value. Fourth, the role of other PARP family members should be considered. For
example, PARP16 has been shown to contribute to cell stress and unfolded protein
responses (Jwa and Chang, 2012), pathways known to be altered in cancers. Finally, what is
the contribution of PARP2 to clinical responses to PARP inhibitors? Most agents that have
been utilized in clinical trials effectively suppress the activity of both PARP1 and PARP2;
while preclinical studies point to PARP1 as the critical therapeutic target, the contribution of
PARP2 to clinical responses cannot be dismissed, and a richer understanding of PARP2
mediated molecular and cellular activities would be of likely benefit for interpreting clinical
data. Overall, recent findings have clearly invigorated translational and clinical interest in
PARP1 inhibitors for use in oncology care, cardiovascular dysfunction, and inflammatory
diseases, while biochemical dissection and preclinical modeling has potentiated our
understanding of PARP1 inhibitor function from chromatin to the clinic. The molecular
basis of PARP1 inhibitor function remains fertile ground for translational discovery.
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Figure 1.

Schematic highlighting the translational implications of the dual roles of PARP1 in DNA
repair and transcriptional regulation.
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Distribution of PARP inhibitor trials by various characteristics.
PARP inhibitor studies were identified on the clinical trial repository website
(www.clinicaltrials.gov) using the keyword “PARP”. This search, completed in early March
of 2015, identified 149 trials. Of these studies, 33 were excluded because they had been
withdrawn prior to enrollment or because they did not utilize a true PARP inhibitor.
Specifically, it should be noted that all studies including iniparib (BSI-201) were excluded,
as it has been determined that this agent actually has poor selectivity toward PARP function,
and does not meet the current criteria for a bona fide PARP1 inhibitor (Patel et al., 2012). Of
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the remaining 116 studies, the distribution of trials is shown by indication (cancer vs noncancer indication) in Figure 2A and by phase (0–3) in Figure 2B. Of the 112 studies using
PARP1 as cancer therapy, the distribution of these trials is then shown by disease site
(Figure 2C), therapy (mono- vs combination therapy, Figure 2D), and by biomarker
selection (Figure 2E).
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